Clonazepam

Evidence Level: L3

Predicted Indications: 3

Clonazepam

Pharmacist Assessment Report

Clonazepam: GABA-A receptor positive allosteric modulator (benzodiazepine) → restless legs syndrome

One-Sentence Summary

Clonazepam is a benzodiazepine that acts on GABA-A receptors and is registered in Australia as Rivotril tablets. The TxGNN model predicts it may be useful for restless legs syndrome, but there are no registered clinical trials and the evidence pack contains only a small number of studies that directly examine clonazepam in this condition (one 1984 crossover trial, one 2001 sleep-laboratory study, a Cochrane review of benzodiazepines, and a 2025 comparison with dopamine agonists).

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	restless legs syndrome
TxGNN Prediction Score	0.9965
Evidence Level	L3
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Clonazepam is a positive allosteric modulator of the GABA-A receptor. Enhancing inhibitory GABA signalling may reduce sensory-motor arousal and sleep fragmentation, which are prominent in restless legs syndrome (RLS) and periodic limb movements during sleep.

Detailed mechanism-of-action data were not available in the data compiled for this report, so the mechanistic link above is a plausible rationale rather than a confirmed pathway.

Clinical support is modest. A small randomised, double-blind, placebo-controlled crossover trial of six patients (1984) reported improved subjective sleep quality and leg dysaesthesia. A Cochrane systematic review of benzodiazepines for RLS (2017) is also available. However, the 2025 American Academy of Sleep Medicine guideline does not favour benzodiazepines as first-line therapy, so clonazepam is at most a second-line or adjunct option.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39324694	2025	Guideline	J Clin Sleep Med	AASM clinical practice guideline on treatment of RLS and periodic limb movement disorder in adults and children
28319266	2017	Systematic review	Cochrane Database Syst Rev	Benzodiazepines, particularly clonazepam, are used for RLS symptoms because they help induce and maintain sleep
36692194	2023	Systematic review / meta-analysis	J Clin Sleep Med	Drug categories effective in suppressing periodic limb movements in RLS
18925578	2008	Review	Mov Disord	Movement Disorder Society evidence-based review of RLS treatments
6380197	1984	Randomised crossover trial (6 patients)	Acta Neurol Scand	Clonazepam significantly improved subjective sleep quality and leg dysaesthesia versus placebo; long-term efficacy needs confirmation
11313161	2001	Placebo-controlled sleep laboratory study	Eur Neuropsychopharmacol	Acute effects of 1 mg clonazepam on objective and subjective sleep in RLS and periodic limb movement disorder
20156514	2010	Clinical study	Prog Neuropsychopharmacol Biol Psychiatry	Proposed dose equivalence between clonazepam and pramipexole in RLS
39787099	2025	Clinical study	Sleep	Differential effects of dopamine agonists and clonazepam on large muscle group movements in RLS
24363103	2014	Review	Neurotherapeutics	Overview of changing RLS treatment options
35426627	2022	Review	Am Fam Physician	Diagnosis and management of common adult sleep disorders, including RLS

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11520H	Rivotril	Tablet 500 micrograms	Not recorded in the local data

Safety Considerations

The contraindication and warning text from the TGA-approved Product Information was not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.

Drug Interactions (100 interactions recorded; selected examples):

Major: morphine (including liposomal morphine). Combined central nervous system and respiratory depression is the key concern.
Moderate: bupropion, aprepitant, omeprazole, cimetidine, clarithromycin, dronabinol, metoclopramide, nabilone, opium, sibutramine, teduglutide.
Minor: antacids such as magnesium oxide, aluminium hydroxide and calcium carbonate.

Conditions flagged as problematic for this drug in the data compiled (not taken from label text): liver failure and liver disease, kidney disease, respiratory failure, sleep apnoea syndromes, angle-closure and open-angle glaucoma, porphyria, and substance-related disorders or dependence. These should be checked against the PI before any use.

Clinical literature also notes dependence, tolerance and next-day sedation with benzodiazepines.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Clonazepam already has an Australian registration, and small controlled studies plus a Cochrane review support a modest benefit in restless legs syndrome. Current guidance places benzodiazepines behind other therapies, so any use should be as a second-line or adjunct option under clear safeguards.

To proceed, the following is needed:

Review of the TGA-approved Product Information for warnings and contraindications
Larger, modern randomised trials of clonazepam in restless legs syndrome, including long-term efficacy
Comparison against current first-line therapies per the 2025 AASM guideline
A plan to monitor for dependence, tolerance, sedation and respiratory depression, particularly with opioids
Detailed mechanism-of-action data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.